Friday, 17 Nov 2017

You are here

Good News from ACR17 - Gout

The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

Visit our RheumNow annual meeting site to read our gout content - http://acr17.rheumnow.com/category/gout-crystal/

Specific items:

  • Treatment of hyperuricemia to prevent incident dementia? Some data suggests this. Abstract #2076
  • PossibleGout and OA connection? Human cartilage increases amount and size of MSU crystals. Abstract #2896 http://ow.ly/ABLg30fM2gw
  • Low Uric acid may raise the risk of dementia. Abstract #2080
  • Lower coffee consumption is associated with gout!  Abstract #2066
  • Allopurinol and Febuxostat in lowes the risk of Dementia. Yes you read that right! Jas Singh et al. Abstract #2076
  • Both generic and environmental factors influence the fractional excretion of uric acid Abstract #2061
  • Hyperuricemia is associated with more rapid knee osteoarthritis progression. A&R 2017
  • Tollerizing pegloticase regimen decreases infusion reactions in the TRIPLE study Abstract #1141
  • Gout is under treated people… need to get better  Abstract #1121
  • If you have gout and type II diabetes you have worse gout. More tophi and erosions. Abstract #1118
  • Uncontrolled gout is associated with more heart failure so treat gout effectively. Abstract #1119
  • Risk for CV events lower with the new start probenecid (rather than allopurinol) for older >65 yo patients Abstract #159
  • Dr. Daniel Solomon YR in Review – the DASH diet decrease gout risk https://doi.org/10.1136/bmj.j1794 
  • Diuretics don’t seem to impact hugely on gout treatment objectives in this study Abstract #1129
  • Patients aren’t getting to urate target in gout when treated with allopurinol. Are we using enough? Abstract #166
  • Do we need to change the label ‘gout’ ?!?!? Has negative stereotypes  Abstract #1107
  • Patients with gout have their XOI stopped when they present with AKI. Evidence free zone and makes gout Rx harder. Abstract #1116
  • Gout patients more likely to achieve sUA goal< 6 mg/dL if managed by a rheumatologist. Go team Rheum! Abstract #166
  • Pre-Rx with methylprednisolone superior to HC as prophylaxis for pegloticase w/ greater drug survival  Abstract #213 https://buff.ly/2hKNl3y
  • Double contour sign - earliest sign of uric acid deposition obs in asymptomatic gout pts. Abstract #250 http://ow.ly/YZtb30fDVzZ
  • US of MTP1, distal patellar/triceps tendons, talar + femoral cartilage for MSU in possible gout Abstract #249
  • FORTUNE1: stepwise  Uloric dose comparable to colchicine+Uloric in flare prevention during introductory Rx 
  • Cankinumab reduces CV events, decreases risk of gout & malignancy. Higher infection risk  #YearInReview
  • “Gout patients can have septic arthritis and sickle cell pts can also have gout. Keep this in mind during your nex sickle cell crisis differential diagnoses.”  – J Cush, MD (Rheumatology Roundup). 

Gout Videos

Dr. Jack Cush: When Asymptomatic Hyperuricemia Should Be Treated 

 

Dr. Arthur Kavanaugh: Gout, OA Posters

 

Dr. Ken Saag: Update on Gout Therapy

 

Dr. Janet Pope: Gout Gamechangers 

Disclosures: 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Ironwood Featured Presentations

Ironwood Pharmaceuticals, Inc. (IRWD) today announced one oral and twelve poster presentations to be presented at the upcoming ACR/ARHP Annual Meeting in San Diego, California from November 3-8, 2017. The meeting is hosted by the American College of Rheumatology and Association of Rheumatology Health Professionals.

Gout Increases Risk of Stroke Moreso than MI

Gout coassociates with many of the disorders within the metabolic syndrome - diabetes, hypertension, hyperlipidemia and obesity.  Not surprisingly, gout is a risk factor for cardiovascular disease, but the risk magnitude for  myocardial infarction (MI), and stroke are unclear.

Pegloticase Infusion Reactions Largely Seen in Non-Responders

The introduction of intravenous pegloticase (PEG) in 2010 was felt by many to be a major advance in the treatment of patients with severe, refractory tophaceous gout.  But for some, concerns over infusion reactions and safety have limited its use.

Gouts' Increasing Hospitalizations and Poor Management

Numerous studies have shown that gout hospitalizations have increased in the last decade. Also worrisome is a new studiy showing that patients admitted to the hospital are less likely to have received recommended urate-lowering treatment (ULT). (Abstract OP0262 - http://buff.ly/2roN7SF)

Mixed Results with Combination Therapy in Gout

Lesinurad, a selective URAT-1 inhibitor has been approved for coadministration with a urate-lowering therapy (ULT) in patients with gout for nearly a year. The CRYSTAL study was one of the studies that lead to FDA approval.